

01. Letter from the President
02. Upcoming Events
03. Conference President - Call for Application
04. Job postings
05. CFTR gene mutation analysis in European patients with CF
06. ERS CF Course
07. CF Research EU funded projects
08. Results ECFS Board Elections 2015
09. CTN Expansion
10. JCF Impact factor
11. JCF Research News
12. JCF App
13. Membership
14. ECFS Book Living Longer with CF
15. ECFS Tomorrow
16. Annual General Meeting - Minutes
17. 2015 Brussels Conference Survey
18. Current References in CF

European Cystic Fibrosis Society  
Kastanieparken 7,  
7470 Karup, Denmark  
Tel: +45 86 676260  
Fax: +45 86 676290  
Email: [info@ecfs.eu](mailto:info@ecfs.eu)  
Website: [www.ecfs.eu](http://www.ecfs.eu)

## 01. Letter from the President

Dear Friends,

I hope this finds you well and that you all have had a chance to enjoy some relaxing summer vacation.

For those of you who were able to participate in the June ECFS Conference in Brussels, I am sure you will agree that it was a great success, and I would again like to thank the conference President Georges Casimir, and the Vice Presidents, Mario Vaneechoutte and Ulrike Pypops for their contribution to the event. I would also like to thank the Cystic Fibrosis Association of Belgium and all their considerable and enthusiastic support. My sincere thanks go to the Scientific Committee who produced an excellent programme, and to the speakers, moderators and presenters for their superb contribution.

The ECFS continued its tradition of awarding Travel Grants to young researchers based on the merit of their submitted abstracts, and we were delighted to welcome the 3 Young Investigator Awardees to the Opening Ceremony. All the award winners also received a 1 year free membership subscription to the ECFS.



Young Investigator Awards 2015:  
Rebecca Keyte (UK) Susanne Dittrich (DE) Emma Reece (IE)

To honour the enormous contribution of Prof. Gerd Döring, the ECFS has initiated a Gerd Döring Award that will be given annually to honour an exceptional early career young European scientist.

This award includes a monetary grant of € 5000 to support research.

The first Gerd Döring Award was presented to Florijn Dekkers (NL)

[More information on the ECFS Awards:](#)



Once again, speakers at this year's conference were asked to make their presentations (slides) available on the ECFS website (for members only) and these can be viewed by signing in under the "MY ECFS" tab in the top banner of our website [www.ecfs.eu](http://www.ecfs.eu).

Thank you to all of you who participated to the Board elections in May. I would like to warmly congratulate Isabelle Fajac, Daniel Peckham and Harm Tiddens. It's a pleasure to welcome them to the Board and we look forward to their input.

Again, I would like to thank Dominique Hubert and Milan Macek, our departing Board members for their commitment and support during their term in office.

How can we thank Stuart Elborn for his 8 years of fantastic ECFS leadership of the ECFS?

It is difficult to summarize all his dedication and commitment through the years in a few lines. Significant successes have been achieved for the Society under his leadership amongst which the officialization of working groups, the Clinical trials network, the ECFS Patient Registry new start, the ECFS book series as well as the Standards of Care initiative.

We are well into the planning for the Basic Science Conference which will be held in Italy in the Spring (end March or early April), and the annual conference which will be held 08-11 June 2016 in Basel, Switzerland. Programmes for both conferences will be available soon and we hope that you will take an active part in these events and consider submitting your best work for presentation and discussion. More information about the conferences can be found on our website.

I would like to thank those members who participated in this year's Annual General Meeting in Brussels, and you will find the minutes from the meeting included in this Newsletter.

As always, I would like to remind you to please feel free to send us articles that you would like to have included in forthcoming newsletters as this provides a great vehicle for communication.

Best wishes,

Kris De Boeck, ECFS President

## 02. Upcoming Events

- ECFS Board Meeting 07 October 2015 - Phoenix, Arizona, USA
- 29th North American Cystic Fibrosis Conference 08-10 October 2015 - Phoenix, Arizona, USA
- ECFS Winter Board Meeting - 27 January 2016 - Prague, Czech Republic
- ECFS CTN Steering Group Meeting - 28-29 January 2016 - Prague, Czech Republic
- ECFS Patient Registry Steering Group Meeting - 29 January 2016 - Prague, Czech Republic
- ECFS Diagnostic Network Working Group Meeting - February 2016, London, UK
- 10th European Young Investigators Meeting - 10-12 February 2016
- ECFS 13th Basic Science Conference - end March 2016 - Italy
- ECFS Board Meeting - 07 June 2016 - Basel, Switzerland
- 38th European CF Conference - 08-11 June 2016 - Basel, Switzerland



## 03. Conference President and Conference Vice President – Call for Application

Further to a recent decision of dissociating country of venue of the ECFS conference and nationality of Conference President, the ECFS cordially invites applications for the positions of ECFS Conference President and Vice-President for the 2017 ECFS Conference.

Job Descriptions and person specifics are available [here](#).

Applications should be sent to the ECFS Executive Director Christine Dubois (christine.dubois@ecfs.eu) by **25 September 2015** using the application form available on the website together the required documentation. All applicants must be current members of the ECFS.

## 04. Job postings

### PhD Fellowship - BioSys Lisbon, Portugal.

The Biosystems and Integrative Sciences Institute (BioSys) PhD Programme in Biological Systems - Functional and Integrative Genomics is an international programme for talented and highly motivated students of any nationality.

Applications for the 2016 edition are open

Click [here](#) to have more details

## 05. CFTR gene mutation analysis in European patients with CF

This new research initiative aims to provide a service for highly parallel sequencing of the complete CFTR gene (including intronic and promoter regions) in patients with confirmed CF (maximum 5 patients per individual site) in whom a disease-causing mutation was not found on both CFTR genes.

Project Leaders: Harry Cuppens (geneticist) and Kris De Boeck (clinician)

In cooperation with the ECFS Diagnostic Network Working Group (Nico Derichs)

Supported by a grant from Vertex Pharmaceuticals

Click [here](#) for more information

## 06. ERS CF Course

The ERS organises a 3 day course on CF in Prague, Czech Republic on 19-21 November 2015.

This course approaches CF from a multi-disciplinary and collaborative approach. The important topics of epidemiology, diagnosis, pathophysiology of CF, treatment, and psychological issues are covered, as well as the key factors involved in the organisation of CF care. Two specific tracks will be available for paediatric and adult care. Click [here](#) to find details.

## 07. CF Research EU funded projects

We have listed the main EU funded projects related to CF research.

Click [here](#) to find details.

## 08. Results ECFS Board Elections 2015

We are happy to announce that Isabelle Fajac, Daniel Peckham and Harm Tiddens have been elected as ECFS Board members.

We would like to take this opportunity to warmly thank Dominique Hubert and Milan Macek for their commitment through the years.

Stuart Elborn finished his mandate as president of the ECFS.

We warmly thank him for all his work through the years. With his strategy and efforts he made significant changes to the Society.



## 09. ECFS CTN Expansion



A new expansion of the network was announced in 2014 to increase the current capacity. CF centres specialized in clinical trials were invited to send their application by the beginning of 2015.

37 applications were received, scored and evaluated by a selection committee. At the end of this process, 13 sites with the highest ranking were selected to join the ECFS-CTN. Four new countries are involved (Ireland, Israel, Poland and Switzerland) and the network now covers around 17500 adult and pediatric CF patients in 15 countries and 43 sites.

A full list of ECFS-CTN sites can be found on <https://www.ecfs.eu/ctn/list-ctn-centres>. The new sites are now being prepared to actively participate in the network as from 2016

## 10. JCF Impact factor

The journal impact factors for 2014 slightly decreased from 3.82 in 2013 to 3.475. JCF now ranks 14th in the Respiratory category. Based on the number of articles published and cites over the last 18 months, the impact factor is very likely to increase in 2015.

## 11. JCF Research News

CF Research News offers lay version summaries of the most recent articles published in the Journal of Cystic Fibrosis. The aim of this new initiative is to bridge the gap between people with CF and the researchers investigating CF and how best to treat those with the condition.

We aim to provide access to all scientific work published in the Journal of Cystic Fibrosis (JCF) to patients, parents, relatives, friends and caregivers of people with CF.

To access CF Research News click [here](#)

## 12. JCF App

A Journal of Cystic Fibrosis Mobile App is now available on iOS and Android



In the Know, On the Go with the  
*Journal of Cystic Fibrosis*  
Mobile App for iOS and Android



## Get Your Information Anytime, Anywhere – online or off

Free for European Cystic Fibrosis Society  
Members & Journal Subscribers



### KEY BENEFITS

- ★ Get access to the latest issue or view the journal archive
- 🔍 Use the free text search to find what you want to read
- 📄 Quickly and conveniently get to the content you want, with easy navigation and layouts
- 📺 Watch videos and interact with images, tables, and more
- 📌 Highlight, notate and share articles and save your favorites for convenience

[Cysticfibrosisjournal.com](http://Cysticfibrosisjournal.com)  
Get Access  
[bit.ly/cysticfibrosisjournalapp](http://bit.ly/cysticfibrosisjournalapp)



Download **TODAY**




## 13. Membership

We are happy to announce that for the first time the ECFS exceeds 1000 members. We currently have 1035 members to be accurate!

Click [here](#) to review our membership advantages.

## 14. ECFS Book Living Longer with CF



We are happy to announce that the second Edition of the ECFS Book, Living Longer with Cystic Fibrosis, is now available.

Many thanks go to Dominique Hubert and Nicholas Simmonds, Editors of the book for their hard work. We hope that this book will help to attract more adult care physicians to the field of CF.

The book has been sent to all ECFS members in July.

## 15. ECFS Tomorrow

The second edition of the ECFS Tomorrow in Brussels was a great success.

Over the four days of conference, people from our multidisciplinary community researching and treating Cystic Fibrosis could meet at the ECFS Tomorrow Lounge to exchange ideas.

Alexandra Quittner and Dominik Hartl ran workshops on *Writing successful grants* and on *How to establish a research group*.

All participants were enthusiastic about the initiative.

In Brussels, we also launched an ECFS Tomorrow Networking Event. During this relaxing evening friends and colleagues had the opportunity to meet new people and exchange experiences. We organized a quiz on Belgium and beers as well as on CF. We would like to thank Dominik Hartl who was a perfect quiz presenter!

The price for the winner team was a free registration to the Annual conference in Basel next year...and the winner is Julia Hentschel. Get ready for the next edition in Basel!



## 16. Annual General Meeting Minutes

### Minutes of the Annual General Meeting of the European Cystic Fibrosis Society

#### **38th European Cystic Fibrosis Conference, Brussels, Belgium, 10th June 2015**

Presiding Officer: Prof. Kris De Boeck

The meeting was opened at 17.00.

Number of Participants: 103

#### President's Report

Prof. Kris De Boeck welcomed the ECFS members present and thanked them for their participation in the meeting. She thanked Prof Stuart Elborn for his drive of the society over the past 8 years and the numerous achievements for the society under his leadership, amongst which the launch of the ECFS Clinical Trials Network, the development of ECFS Working Groups, the new start of the ECFS Patient Registry, the Standards of Care initiative and the launch of the ECFS Book series.

Prof. Elborn thanked for the years in the ECFS and acknowledged the support received from Prof. Döring, the Board Members and the ECFS staff around Christine Dubois. He thanked Prof. De Boeck for the smooth handover and reiterated his trust in very successful years to come for ECFS under her leadership.

Prof. De Boeck presented the plans ahead for the society.

- Generalization of 3 year terms for leadership roles at the ECFS
- ECFS elections via e-voting also available during the ECFS conference
- Application form for Conference President and Vice President
- Dissociation country of venue and nationality of Conference President
- Monthly teleconference of the ECFS Board
- Further collaboration across continents
- Defining research priorities
- Eg. Academic research to bring treatment to patients with rare *CFTR* mutations: strategic alignment between basic research, patient organization and clinical trial network
- Delineating joint projects with Patient Organisations (she took this opportunity to congratulate the newly elected CFE President, Jacquélien Noordhoek)

Prof. De Boeck mentioned some of the challenges ahead for CF and the society.

- Research capability and resourcing
- Horizon 2020
- Funding Precision Medicine

She reported that about 2300 delegates had registered for the Brussels conference and that 541 abstracts had been submitted. She took the opportunity to thank the Conference President and Conference Vice Presidents and all the other organizers for their contribution to a smooth preparation of the conference.

She went on to provide an overview of the ECFS activities over the last year, beginning with the Steering Committee meetings of the CTN and ECFSPR in January and the ECFS Diagnostic Network Working Group meeting in Warsaw in February. She mentioned the highly successful Basic Science

conference held in Albufeira, Portugal, where a record number of attendees and abstract submissions were recorded. She encouraged all to attend this very important conference. She presented a slide listing the current ECFS Projects and Working Groups, and noted that reports on these activities had been provided ahead of the meeting and Coordinators of these projects would be ready to answer questions on their activities later on in the meeting. She announced the launch of CF Research News providing lay summaries of articles published in JCF and thanked Dr Harry Heijerman for taking the lead on this initiative.

Finally, she announced the recently published ECFS Book, 'Living longer with CF'. She thanked the Editors, Dr Nick Simmonds and Dr Dominique Hubert for their hard work and encouraged all to visit the ECFS stand at the conference to take their copy of the ECFS Book.

The President then presented the programme of activities for 2015-2016 to include:

7 Oct. 2015	ECFS Board Meeting - Phoenix, Arizona, USA
27 Jan. 2016	ECFS Winter Board Meeting - Prague, Czech Republic
28-29 Jan. 2016	ECFS CTN Steering Group- Prague, Czech Republic
29 Jan. 2016	ECFS Patient Registry Steering Group Meeting - Prague, Czech Republic
Feb. 2016	ECFS Diagnostic Network Working Group Meeting, London, UK
10-12 Feb.2016	10th European Young Investigators Meeting Paris, France
End Mar.2016	ECFS 13th Basic Science Conference, Italy (tbc)
07 June 2016	ECFS Board Meeting - Basel, Switzerland
08-11 June 2016	39th European CF Conference - Basel, Switzerland

She thanked the departing ECFS Board Members for their commitment over the years and ended her report by thanking the ECFS Membership, the National Patient Organisations, the Pharmaceutical Industry, and International collaborators for their continuing support of ECFS activities.

The audience was asked for any questions: None received.

### Secretary's Report

Prof. Milan Macek reported the preliminary membership numbers for 2015 (May) were 921, an increase in comparison with the figures reported at the same time frame in 2014. One of the reasons for this was the introduction of conference registration and membership subscription available to all attendees.

In view of the healthy financial situation of the Society, he was happy to inform the membership that there would be no increase to the standard subscription fee in 2016; it will remain at Euro 120. There will be a continued lower rate for some categories of members who do not wish to receive the Journal of Cystic Fibrosis (JCF):

- Allied Health Professionals - 50 € (\*)
- PhD Students and Post Docs - 70 € (\*)
- Retired members still actively engaged in an ECFS Project or Working Group - Free (\*)

The discounted 3 years subscription (300 € instead of 360 €) introduced in 2015 will be offered as a membership possibility for the years 2016-2017-2018

He reminded the audience that following discussions with Elsevier, the JCF publishers, all articles included in the Journal which are more than 2 years old are now freely available for download.

He thanked Dominique Hubert, Carlo Castellani and Stuart Elborn who completed their term on the ECFS Board for their time and valuable contribution to the ECFS Board during their term in office and thanked all for their support, this being his last meeting as a Member of the ECFS Board.

He communicated the results of the recent elections and was happy to announce the election of 3 Board members, Prof. Isabelle Fajac, Prof. Harm Tiddens and Dr. Daniel Peckham.

The audience was asked for any questions: None received.

### Treasurer's Report

Prof. Tania Pressler presented the audited ECFS Financial statement for the year 2014. The result of the year showed a deficit of € -164,513 due to extra support needed for some ECFS activities. The ECFS Patient Registry received extra support to cover the accumulated deficit and have a start of the year 2015 at 0 balance. For the Standards of care initiative, the support covered the accumulated expenses over 3 years for the whole project (including Consensus meeting - publication of a supplement and Open access). Despite this negative year result, the audited accounts show a positive balance for the Society's net assets of € 3,053,552 at 31st December 2014. Prof. Pressler informed the AGM that the full audited accounts will be posted on the website.

### Report from ECFS CTN

Dr. Tim Lee presented a graph demonstrating the progression of studies conducted by the CTN since 2009.

Among the achievements and milestones:

- Since 2009, 62 protocols have been reviewed
- Since 2011, 24 feasibility checks have been performed
- Participation in EMA workshop to standardize outcome measures and priorities for CF Clinical Trials - and ongoing advice/consultation
- Involvement in Enpr-EMA committees and working groups

Dr. Lee also acknowledged the financial support received from some National CF Patient Organisations and from the US CF Foundation. He announced the expansion of the Clinical Trials Network to include 13 new sites from January 2016.

### Report from ECFS Patient Registry

Dr. McKone reported on the activities of the ECFS Patient Registry (ECFSPR).

The ECFSPR is expanding its coverage with 28 countries participating and over 32,000 CF patients. He reported that the new software, ECFS Tracker was launched in January with stages roll-out over Europe.

He announced the ECFSPR aimed to publish the 2011-2013 data report early 2016.

Activities:

- Recruitment of new countries is ongoing
- A new business plan is being developed for the ECFSPR

Finally, Dr. McKone thanked the project's sponsors and collaborators.

### Update on Journal of Cystic Fibrosis

Dr. Scott Bell reported on developments of JCF since the start of his office. The acceptance rate is currently at 26%.

Based on the page budget, the number of paper published per annum should be in the region of 110  
- 120.

He presented a slide showing a decrease in time required to make the first decision.

There has been a steady increase of submitted articles (178 as of 3 June 2015) and a corresponding rise in the number of Science Direct downloads.

New initiatives and recent changes include:

- Composition of Editorial Board and Terms of Reference
- Streamline MS handling (finding 'reviewers' is real challenge)
- Editorials in each issue
- “Invited Review” series currently running (Micro and Basic Science)
- Highlights (“News” section)
- Lay Journal (“CF Research News”)
- Online only publications
- Social media and the Journal - work in progress
- CME initiative

### Reports from ECFS Working Groups

Prior to the Annual General Meeting, members had been sent the progress reports from the ECFS Working Groups. The audience was asked for any questions: None received.

Current Working Groups:

Diagnostics Network Working Group

Exercise Working Group

Neonatal Screening Working Group

Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science Working Group

### Special Interest Groups

Prof De Boeck announced that the following groups had been approached to gauge their interest in being affiliated to the ECFS as Special Interest Groups:

- International Nurse Specialist Group
- European Cystic Fibrosis Nutrition Group
- European Psychosocial Interest Group
- International Physiotherapy Group for Cystic Fibrosis
- Pharmacists

### Annual Conference 2016

A slide was shown presenting the 39th ECFS conference, to be held in Basel, Switzerland, 8-11 June 2016.

Questions/Comments received: None

### Any Other Business

- Membership: Michael Wilschanski suggested reducing to 50 Euro the membership fee for young people in order to increase the membership numbers. It was agreed this would be further discussed by the ECFS Board.
- Membership of Industry representatives: Nico Derichs reported on recent request of industry representatives to be full member of the Diagnostic Working Group.  
➔ Question to the AGM: Should corporate members from industry be allowed to be members of ECFS Working Groups?  
The audience voted almost unanimously against allowing corporate members from industry to be members of ECFS Working Groups.

With no further items being raised, the meeting ended at 18.00.

## 17. 2015 Brussels Conference Survey - Free Registration Winners

The ECFS would like to thank all those who took the time to answer the ECFS 2015 Survey after the conference in Brussels. The answers and comments help us to keep on improving our conferences. As announced, three free registrations to the next ECFS Conference in Basel were selected from the respondents.

We congratulate the winners:

Galit Livnat Levanon (IL)

Matthew Moore (UK).

Martin Zapalka (CZ)

## 18. Current References in CF

### CF References

#### Adults & Adolescents

**Schram CA., Stephenson AL., Hannam TG., Tullis E.**  
Cystic fibrosis (CF) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (AMH) in young women  
*Journal of Cystic Fibrosis* 2015; 14: 398 – 402

#### Animal Model

**Bazett M., Honeyman L., Stefanov AN., Pope CE., Hoffman LR., Haston CK.**  
Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome  
*Mammalian Genome* 2015; 26: 222 - 234

**Bodewes FAJA., van der Wulp MYM., Beharry S., Doktorova M., Havinga R., Boverhof R., Phillips MJ., Durie PR., Verkade HJ.**  
Altered intestinal bile salt biotransformation in a cystic fibrosis (Cftr(-/-)) mouse model with hepato-biliary pathology  
*Journal of Cystic Fibrosis* 2015; 14: 440 - 446

**Dhooghe B., Bouckaert C., Capron A., Wallemacq P., Leal T., Noel S.**  
Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice  
*Biology Open* 2015; 4: 929 - 936

**Galluzzo M., Ciraolo E., Lucattelli M., Hoxha E., Ulrich M., Campa CC., Lungarella G., Doring G., Zhou-Suckow Z., Mall M., Hirsch E., De Rose V.**  
Genetic Deletion and Pharmacological Inhibition of PI3K gamma Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease  
*Mediators of Inflammation* 2015; : ArNo: 545417

**Liu XM., Li TL., Riederer B., Lenzen H., Ludolph L., Yeruva S., Tuo BG., Soleimani M., Seidler U.**  
Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO<sub>3</sub><sup>-</sup> transport and reduces survival in CFTR-deficient mice  
*Pflugers Archiv-European Journal Of Physiology* 2015; 467: 1261 - 1275

**Woods PS., Tazi MF., Chesarino NM., Amer AO., Davis IC.**  
TGF-beta-induced IL-6 prevents development of acute lung injury in influenza A virus-infected F508del CFTR-heterozygous mice  
*American Journal of Physiology-Lung Cellular and Molecular Physiology* 2015; 308: L1136 - L1144

#### Antimicrobials

**Abdulla A., van Leeuwen RWF., Schultink AHMD., Koch BCP.**  
Stability of colistimethate sodium in a disposable elastomeric infusion device  
*International Journal of Pharmaceutics* 2015; 486: 367 - 369

**Antoniou S.**  
Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis  
*Expert Review of Anti-Infective Therapy* 2015; 13: 897 - 905

**Baelo A., Levato R., Julian E., Crespo A., Astola J., Gavalda J., Engel E., Mateos-Timoneda MA., Torrents E.**  
Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections  
*Journal of Controlled Release* 2015; 209: 150 - 158

**Beigelman A., Isaacson-Schmid M., Sajol G., Baty J., Rodriguez OM., Legee E., Lyons K., Schweiger TL., Zheng J., Schechtman KB., Castro M., Bacharier LB.**  
Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis  
*Journal of Allergy and Clinical Immunology* 2015; 135: 1171 - U543

**Belotti S., Rossi A., Colombo P., Bettini R., Rekkas D., Politis S., Colombo G., Balducci AG., Buttini F.**  
Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation  
*European Journal of Pharmaceutics and Biopharmaceutics* 2015; 93: 165 - 172

**Casciaro R., Cresta F., Naselli A., Castagnola E.**  
Comment to Letter to the Editor regarding the article by R. Casciaro et al. titled 'Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: case report and review of literature'  
*Journal of Chemotherapy* 2015; 27: 255

**Chalhoub H., Tunney M., Elborn JS., Vergison A., Denis O., Plesiat P., Kahl BC., Van Bambeke F., Tulkens PM.**  
Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients  
*Journal of Antimicrobial Chemotherapy* 2015; 70: 1596 - 1598

**Chatzimoschou A., Simitopoulou M., Antachopoulos C., Walsh TJ., Roilides E.**  
Antipseudomonal Agents Exhibit Differential Pharmacodynamic Interactions with Human Polymorphonuclear Leukocytes against Established Biofilms of Pseudomonas aeruginosa  
*Antimicrobial Agents and Chemotherapy* 2015; 59: 2198 - 2205

**Ciofu O., Tolker-Nielsen T., Jensen PO., Wang HZ., Hoiby N.**  
Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients  
*Advanced Drug Delivery Reviews* 2015; 85: 7 - 23

**Claus BOM., Snauwaert S., Haerynck F., Van Daele S., De Baets F., Schelstraete P.**  
Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients  
*International Journal Of Clinical Pharmacy* 2015; 37: 555 - 558

**Dasenbrook EC., Konstan MW., VanDevanter DR.**  
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes  
*Journal of Cystic Fibrosis* 2015; 14: 370 - 375

**Du J., Bandara HMHN., Du P., Huang H., Hoang K., Nguyen D., Mogarala SV., Smyth HDC.**  
Improved Biofilm Antimicrobial Activity of Polyethylene Glycol Conjugated Tobramycin Compared to Tobramycin in Pseudomonas aeruginosa Biofilms  
*Molecular Pharmaceutics* 2015; 12: 1544 - 1553

**Dubee V., Soroka D., Cortes M., Lefebvre AL., Gutmann L., Hugonnet JE., Arthur M., Mainardi JL.**  
Impact of beta-Lactamase Inhibition on the Activity of Ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus  
*Antimicrobial Agents and Chemotherapy* 2015; 59: 2938 - 2941

**Francisco GR., Nora STR., Bueno MFC., de Silva LVRF., Garcia DD.**  
Identification of Aminoglycoside-Resistant Pseudomonas aeruginosa Producing RmtG 16S rRNA Methyltransferase in a Cystic Fibrosis Patient  
*Antimicrobial Agents and Chemotherapy* 2015; 59: 2967 - 2968

**Gautam V., Shafiq N., Singh M., Ray P., Singhal L., Jaiswal NP., Prasad A., Singh S., Agarwal A.**  
Clinical and in vitro evidence for the antimicrobial therapy in Burkholderia cepacia complex infections  
*Expert Review of Anti-infective Therapy* 2015; 13: 629 - 663

**Guerra L., Favia M., Castellani S., Barbuti G., Montemurro P., Diana A., Santostasi T., Polizzi AM., Mariggio MA., Reshkin SJ., Manca A., Casavola V., Conese M.**

Antibiotic therapy affects functional behaviour in cystic fibrosis blood mononuclear cells

*European Respiratory Journal* 2015; 46: 558 - 561

**Katelari A., Petrocheilou A., Doudounakis S., Kaditis A.**

Letter to the Editor regarding the article by R. Casciaro et al. titled: 'Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: case report and review of literature'

*Journal of Chemotherapy* 2015; 27: 253 - 254

**Muller U., Hentschel J., Janhsen WK., Hunniger K., Hipler UC., Sonnemann J., Pfister W., Boer K., Lehmann T., Mainz JG.**

Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy

*Mediators of Inflammation* 2015; : ArNo: 626530

**Pedersen MG., Jensen-Fangel S., Olesen HV., Tambe SDP., Petersen E.**

Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis

*BMC Infectious Diseases* 2015; 15: ArNo: 290

**Pompilio A., Crocetta V., Pomponio S., Fiscarelli E., Di Bonaventura G.**

In vitro activity of colistin against biofilm by *Pseudomonas aeruginosa* is significantly improved under "cystic fibrosis-like" physicochemical conditions

*Diagnostic Microbiology and Infectious Disease* 2015; 82: 318 - 325

**Principi N., Blasi F., Esposito S.**

Azithromycin use in patients with cystic fibrosis

*European Journal of Clinical Microbiology & Infectious Diseases* 2015; 34: 1071 - 1079

**Rodriguez-Beltran J., Cabot G., Valencia EY., Costas C., Bou G., Oliver A., Blazquez J.**

N-Acetylcysteine Selectively Antagonizes the Activity of Imipenem in *Pseudomonas aeruginosa* by an OprD-Mediated Mechanism

*Antimicrobial Agents and Chemotherapy* 2015; 59: 3246 - 3251

**Sanchez-Solis M., Gartner S., Bosch-Gimenez V., Garcia-Marcos L.**

Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis

*Allergologia et Immunopathologia* 2015; 43: 298 - 303

**Shahbazi F., Dashti-Khavidaki S.**

Colistin: efficacy and safety in different populations

*Expert Review of Clinical Pharmacology* 2015; 8: 423 - 448

**Stellari F., Bergamini G., Sandri A., Donofrio G., Sorio C., Ruscitti F., Villetti G., Assael BM., Melotti P., Lleo MM.**

In vivo imaging of the lung inflammatory response to *Pseudomonas aeruginosa* and its modulation by azithromycin

*Journal of Translational Medicine* 2015; 13: ArNo: 251

**Thellin O., Zorzi W., Jolois O., Elmoualij B., Duysens G., Cahay B., Streel B., Charif M., Bastin R., Heinen E., Quatresooz P.**

In vitro approach to study the synergistic effects of tobramycin and clarithromycin against *Pseudomonas aeruginosa* biofilms using prokaryotic or eukaryotic culture media

*International Journal of Antimicrobial Agents* 2015; 46: 33 - 38

**Voskamp AL., Gillman A., Symons K., Sandrini A., Rolland JM., O'Hehir RE., Douglass JA.**

Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis

*Journal of Allergy and Clinical Immunology-in Practice* 2015; 3: 192 - 199

**Zemke AC., Gladwin MT., Bomberger JM.**

Sodium Nitrite Blocks the Activity of Aminoglycosides against *Pseudomonas aeruginosa* Biofilms

*Antimicrobial Agents and Chemotherapy* 2015; 59: 3329 - 3334

**Zobell JT., Epps KL., Young DC., Montague M., Olson J., Ampofo K., Chin MJ., Marshall BC., Dasenbrook E.**

Utilization of antibiotics for methicillin-resistant *Staphylococcus aureus* infection in cystic fibrosis

*Pediatric Pulmonology* 2015; 50: 552 - 559

## CFTR

**Abu-Arish A., Pandzic E., Goepp J., Matthes E., Hanrahan JW., Wiseman PW.**

Cholesterol Modulates CFTR Confinement in the Plasma Membrane of Primary Epithelial Cells

*Biophysical Journal* 2015; 109: 85 - 94

**Broadbent SD., Ramjeesingh M., Bear CE., Argent BE., Linsdell P., Gray MA.**

The cystic fibrosis transmembrane conductance regulator is an extracellular chloride sensor

*Pflugers Archiv-European Journal of Physiology* 2015; 467: 1783 - 1794

**Cai ZW., Palmai-Pallag T., Khuituan P., Mutolo MJ., Boinot C., Liu BH., Scott-Ward TS., Callebaut I., Harris A., Sheppard DN.**

Impact of the F508del mutation on ovine CFTR, a Cl<sup>-</sup> channel with enhanced conductance and ATP-dependent gating

*Journal of Physiology-London* 2015; 593: 2427 - 2446

**Dong JD., Jiang XH., Zhang XH., Liu KS., Zhang JT., Chen J., Yu MK., Tsang LL., Chung YW., Wang YR., Zhou WL., Chan HC.**

Dynamically Regulated CFTR Expression and Its Functional Role in Cutaneous Wound Healing

*Journal of Cellular Physiology* 2015; 230: 2049 - 2058

**Dong Q., Ernst SE., Ostedgaard LS., Shah VS., Heul ARV., Welsh MJ., Randak CO.**

Mutating the Conserved Q-loop Glutamine 1291 Selectively Disrupts Adenylate Kinase-dependent Channel Gating of the ATP-binding Cassette (ABC) Adenylate Kinase Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Reduces Channel Function in

*Journal of Biological Chemistry* 2015; 290: 14140 - 14153

**El Hiani Y., Linsdell P.**

Functional Architecture of the Cytoplasmic Entrance to the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Pore

*Journal of Biological Chemistry* 2015; 290: 15855 - 15865

**Gustafsson JK., Linden SK., Alwan AH., Scholte BJ., Hansson GC., Sjoval H.**

Carbachol-induced colonic mucus formation requires transport via NKCC1, K<sup>+</sup> channels and CFTR

*Pflugers Archiv-European Journal of Physiology* 2015; 467: 1403 - 1415

**Ismail N., Giribabu N., Muniandy S., Salleh N.**

Estrogen and Progesterone Differentially Regulate the Levels of Cystic Fibrosis Transmembrane Regulator (CFTR), Adenylate Cyclase (AC), and Cyclic Adenosine Mono-Phosphate (cAMP) in the Rat Cervix

*Molecular Reproduction and Development* 2015; 82: 463 - 474

**Laube M., Bossmann M., Thome UH.**

Glucocorticoids Distinctly Modulate the CFTR Channel with Possible Implications in Lung Development and Transition into Extrauterine Life

*PLoS One* 2015; 10: 4:e0124833

- Le Henaff C., Mansouri R., Modrowski D., Zarka M., Geoffroy V., Marty C., Tarantino N., Laplantine E., Marie PJ.** Increased NF-kappa B Activity and Decreased Wnt/beta-Catenin Signaling Mediate Reduced Osteoblast Differentiation and Function in Delta F508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mice  
*Journal of Biological Chemistry* 2015; 290: 18009 - 18017
- Linsdell P.** Interactions between permeant and blocking anions inside the CFTR chloride channel pore  
*Biochimica et Biophysica Acta-Biomembranes* 2015; 1848: 1573 - 1590
- Londino JD., Lazrak A., Noah JW., Aggarwal S., Bali V., Woodworth BA., Bebek Z., Matalon S.** Influenza virus M2 targets cystic fibrosis transmembrane conductance regulator for lysosomal degradation during viral infection  
*FASEB Journal* 2015; 29: 2712 - 2725
- Loureiro CA., Matos AM., Dias-Alves A., Pereira JF., Uliyakina I., Barros P., Amaral MD., Matos P.** A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint  
*Science Signaling* 2015; 8: 377:ra48
- Lucarelli M., Bruno SM., Pierandrei S., Ferraguti G., Stamato A., Narzi F., Amato A., Cimino G., Bertasi S., Quattrucci S., Strom R.** A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis  
*Molecular Medicine* 2015; 21: 257 - 275
- Malik FA., Meissner A., Semenkov I., Molinski S., Pasyk S., Ahmadi S., Bui HH., Bear CE., Lidington D., Bolz SS.** Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity  
*PLoS One* 2015; 10: 6:e0130313
- McNeer NA., Anandalingam K., Fields RJ., Caputo C., Kopic S., Gupta A., Quijano E., Polikoff L., Kong Y., Bahal R., Geibel JP., Glazer PM., Saltzman WM., Egan ME.** Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium  
*Nature Communications* 2015; 6: ArNo: 6952
- Moon C., Zhang WQ., Ren AX., Arora K., Sinha C., Yarlagadda S., Woodrooffe K., Schuetz JD., Valasani KR., de Jonge HR., Shanmukhappa SK., Shata MTM., Buddington RK., Parthasarathi K., Naren AP.** Compartmentalized Accumulation of cAMP near Complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea  
*Journal of Biological Chemistry* 2015; 290: 11246 - 11257
- Nakano E., Masamune A., Niihori T., Kume K., Hamada S., Aoki Y., Matsubara Y., Shimosegawa T.** Targeted Next-Generation Sequencing Effectively Analyzed the Cystic Fibrosis Transmembrane Conductance Regulator Gene in Pancreatitis  
*Digestive Diseases and Sciences* 2015; 60: 1297 - 1307
- Pesce E., Bellotti M., Liessi N., Guariento S., Damonte G., Cichero E., Galatini A., Salis A., Gianotti A., Pedemonte N., Zegarra-Moran O., Fossa P., Galiotta LJV., Millo E.** Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis  
*European Journal of Medicinal Chemistry* 2015; 99: 14 - 35
- Pizzo L., Iriarte A., Alvarez-Valin F., Marin M.** Conservation of CFTR codon frequency through primates suggests synonymous mutations could have a functional effect  
*Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis* 2015; 775: 19 - 25
- Qian ZQ., Xu XH., Amacher JF., Madden DR., Cormet-Boyaka E., Pei DH.** Intracellular Delivery of Peptidyl Ligands by Reversible Cyclization: Discovery of a PDZ Domain Inhibitor that Rescues CFTR Activity  
*Angewandte Chemie-International Edition* 2015; 54: 5874 - 5878
- Salvatore D., Dell'Edera D., Colangelo C., Smaldore G.** p.Leu636Pro mutation is associated with cystic fibrosis transmembrane conductance regulator-related disorders (congenital bilateral absence of vas deferens)  
*International Journal of Urology* 2015; 22: 803 - 804
- Sancho A., Li SD., Paul T., Zhang F., Aguilo F., Vashisht A., Balasubramanian N., Leleiko NS., Suchy FJ., Wohlschlegel JA., Zhang WJ., Walsh MJ.** CHD6 regulates the topological arrangement of the CFTR locus  
*Human Molecular Genetics* 2015; 24: 2724 - 2732
- Siryani I., Jama M., Rumman N., Marzouqa H., Kannan M., Lyon E., Hindiyyeh M.** Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine  
*PLoS One* 2015; 10: 7:e0133890
- Trouve P., Kerbirou M., Teng L., Benz N., Taiya M., Le Hir S., Ferec C.** G551D-CFTR needs more bound actin than wild-type CFTR to maintain its presence in plasma membranes  
*Cell Biology International* 2015; 39: 978 - 985
- Trzcinska-Daneluti AM., Chen A., Nguyen L., Murchie R., Jiang C., Moffat J., Pelletier L., Rotin D.** RNA Interference Screen to Identify Kinases that Suppress Rescue of Delta F508-CFTR  
*Molecular & Cellular Proteomics* 2015; 14: 1569 - 1583
- van Koningsbruggen-Rietschel S., Naehrlich L.** Cystic fibrosis transmembrane conductance regulator biomarkers in real life: can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?  
*Therapeutic Advances In Respiratory Disease* 2015; 9: 198 - 200
- Wang GY.** Molecular Basis for Fe(III)-Independent Curcumin Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Activity  
*Biochemistry* 2015; 54: 2828 - 2840
- Xie C., Sun X., Chen J., Ng CF., Lau KM., Cai ZM., Jiang XH., Chan HC.** Down-Regulated CFTR During Aging Contributes to Benign Prostatic Hyperplasia  
*Journal of Cellular Physiology* 2015; 230: 1906 - 1915
- Yang LY., Zheng JF., Xiong Y., Meng R., Ma Q., Liu H., Shen H., Zheng S., Wang SL., He JQ.** Regulation of beta 2-adrenergic receptor cell surface expression by interaction with cystic fibrosis transmembrane conductance regulator-associated ligand (CAL)  
*Amino Acids* 2015; 47: 1455 - 1464
- Zhang JY., Hwang TC.** The Fifth Transmembrane Segment of Cystic Fibrosis Transmembrane Conductance Regulator Contributes to Its Anion Permeation Pathway  
*Biochemistry* 2015; 54: 3839 - 3850
- Zinn VZ., Khatri A., Mednieks MI., Hand AR.** Localization of cystic fibrosis transmembrane conductance regulator signaling complexes in human salivary gland striated duct cells  
*European Journal of Oral Sciences* 2015; 123: 140 - 148

## Clinical

### **Milla CE., Moss RB.**

Recent advances in cystic fibrosis  
*Current Opinion In Pediatrics* 2015; 27: 317 - 324

### **Pittman JE., Ferkol TW.**

The Evolution of Cystic Fibrosis Care  
*Chest* 2015; 148: 533 - 542

### **Rizzo LC., Fischer GB., Marostica PJC., Mocelin HT.**

Profile of cystic fibrosis in two reference centers in southern Brazil.  
*Revista Da Associacao Medica Brasileira* 2015; 61: 150 - 155

### **Willis J., Michael DD., Boyer H., Misono S.**

Prevalence and Severity of Dysphonia in Patients with Cystic Fibrosis: A Pilot Study  
*Otolaryngology-Head and Neck Surgery* 2015; 153: 88 – 93

## Diabetes

**Franzese A., Mozzillo E., Fattorusso V., Raia V., Valerio G.**  
Screening of glucose metabolism derangements in pediatric cystic fibrosis patients: how, when, why  
*Acta Diabetologica* 2015; 52: 633 - 638

### **Scheuing N., Thon A., Konrad K., Bauer M., Karsten C., Meissner T., Seufert J., Schonau E., Schofi C., Woelfle J., Holl RW.**

Carbohydrate intake and insulin requirement in children, adolescents and young adults with cystic fibrosis-related diabetes: A multicenter comparison to type 1 diabetes  
*Clinical Nutrition* 2015; 34: 732 - 738

### **Van Sambeek L., Cowley ES., Newman DK., Kato R.**

Sputum Glucose and Glycemic Control in Cystic Fibrosis-Related Diabetes: A Cross-Sectional Study  
*PLoS One* 2015; 10: 3:e0119938

## Diagnosis

### **Doorn J., Storteboom TTR., Mulder AM., de Jong WHA., Rottier BL., Kema IP.**

Ion chromatography for the precise analysis of chloride and sodium in sweat for the diagnosis of cystic fibrosis  
*Annals of Clinical Biochemistry* 2015; 52: 421 - 427

### **Fredj SH., Ouali F., Siala H., Bibi A., Othmani R., Dakhlaoui B., Zouari F., Messaoud T.**

Prenatal diagnosis of cystic fibrosis: 10-years experience  
*Pathologie Biologie* 2015; 63: 126 - 129

### **Groves T., Robinson P., Wiley V., Fitzgerald DA.**

Long-Term Outcomes of Children with Intermediate Sweat Chloride Values in Infancy  
*Journal of Pediatrics* 2015; 166: 1469

### **Keenan K., Avolio J., Rueckes-Nilges C., Tullis E., Gonska T., Naehrlich L.**

Nasal potential difference: Best or average result for CFTR function as diagnostic criteria for cystic fibrosis?  
*Journal of Cystic Fibrosis* 2015; 14: 310 - 316

### **Vermeulen F., Proesmans M., Boon M., De Boeck K.**

Improved repeatability of nasal potential difference with a larger surface catheter  
*Journal of Cystic Fibrosis* 2015; 14: 317 - 323

### **Vernooij-van Langen A., Dompeling E., Yntema JB., Arets B., Tiddens H., Loeber G., Dankert-Roelse J.**

Clinical evaluation of the Nanodot sweat test system in the diagnosis of cystic fibrosis after newborn screening  
*European Journal of Pediatrics* 2015; 174: 1025 – 1034

## Epidemiology

### **Burgel PR., Bellis G., Olesen HV., Viviani L., Zolin A., Blasi F., Elborn JS.**

Future trends in cystic fibrosis demography in 34 European countries  
*European Respiratory Journal* 2015; 46: 133 - 141

### **Dooki MRE., Tabaripour R., Rahimi R., Akhavan-Niaki H.**

Mutation and new polymorphisms insight in introns 11 to 14a of CFTR gene of northern Iranian cystic fibrosis patients  
*Gene* 2015; 564: 193 - 196

### **Kopp BT., Nicholson L., Paul G., Tobias J., Ramanathan C., Hayes D.**

Geographic variations in cystic fibrosis: An analysis of the US CF Foundation Registry  
*Pediatric Pulmonology* 2015; 50: 754 - 762

### **Marion H., Natacha G., Brigitte M., Francois C., Michel R., Corinne T., Emmanuelle G., Thierry B.**

The p.Gly622Asp (G622D) mutation, frequently found in Reunion Island and in black populations, is associated with a wide spectrum of CF and CFTR-RD phenotypes  
*Journal of Cystic Fibrosis* 2015; 14: 305 – 309

## Exercise

### **Bongers BC., Werkman MS., Takken T., Hulzebos EHJ.**

Ventilatory response to exercise in adolescents with cystic fibrosis and mild-to-moderate airway obstruction  
*Springerplus* 2014; 3: ArNo: 696

### **Fielding J., Brantley L., Seigler N., McKie KT., Davison GW., Harris RA.**

Oxygen Uptake Kinetics and Exercise Capacity in Children With Cystic Fibrosis  
*Pediatric Pulmonology* 2015; 50: 647 - 654

### **Parazzi PLF., Marson FAD., Ribeiro MAGD., de Almeida CCB., Martins LC., Paschoal IA., Toro AADC., Schivinski CIS., Ribeiro JD.**

Ventilatory abnormalities in patients with cystic fibrosis undergoing the submaximal treadmill exercise test  
*BMC Pulmonary Medicine* 2015; 15: ArNo: 63

### **Radtke T., Nolan SJ., Hebestreit H., Kriemler S.**

Physical exercise training for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2015; : 6:CD002768

### **Savi D., Di Paolo M., Simmonds N., Onorati P., Internullo M., Quattrucci S., Winston B., Laveneziana P., Palange P.**

Relationship between daily physical activity and aerobic fitness in adults with cystic fibrosis  
*BMC Pulmonary Medicine* 2015; 15: ArNo: 59

## Gastroenterology

### **Kelly T., Buxbaum J.**

Gastrointestinal Manifestations of Cystic Fibrosis  
*Digestive Diseases and Sciences* 2015; 60: 1903 - 1913

### **Lavelle LP., McEvoy SH., Mhurchu EN., Gibney RG., McMahon CJ., Heffernan EJ., Malone DE.**

Cystic Fibrosis below the Diaphragm: Abdominal Findings in Adult Patients  
*Radiographics* 2015; 35: 680 - 695

### **Mascarenhas MR., Mondick J., Barrett JS., Wilson M., Stallings VA., Schall JI.**

Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency  
*Journal Of Clinical Pharmacology* 2015; 55: 854 - 865

### **Morton A., Wolfe S.**

Enteral tube feeding for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2015; : 4:CD001198

**Smith A., Bulman DE., Goldsmith C., Bareke E., Majewski J., Boycott KM., Nikkel SM.**  
Meconium ileus in a Lebanese family secondary to mutations in the GUCY2C gene  
*European Journal of Human Genetics* 2015; 23: 990 – 992

## Gene Therapy

**Griesenbach U., Pytel KM., Alton EFWF.**  
Cystic Fibrosis Gene Therapy in the UK and Elsewhere  
*Human Gene Therapy* 2015; 26: 266 – 275

## Genetics

**Deeb KK., Metcalf JD., Sesock KM., Shen JQ., Wensel CA., Rippel LI., Smith M., Chapman MS., Zhang SL.**  
The c.1364C > A (p.A455E) Mutation in the CFTR Pseudogene Results in an Incorrectly Assigned Carrier Status by a Commonly Used Screening Platform  
*Journal of Molecular Diagnostics* 2015; 17: 360 - 365

**Farhat R., Puissance G., El-Seedy A., Pasquet MC., Adolphe C., Corbani S., Megarbane A., Kitzis A., Ladeveze V.**  
N1303K (c.3909C>G) Mutation and Splicing: Implication of Its c.[744-33GATT(6); 869+11C>T] Complex Allele in CFTR Exon 7 Aberrant Splicing  
*Biomed Research International* 2015; : ArNo: 138103

**McKiernan PJ., Greene CM.**  
MicroRNA Dysregulation in Cystic Fibrosis  
*Mediators of Inflammation* 2015; : ArNo: 529642

**Najafi M., Alimadadi H., Rouhani P., Kiani MA., Khodadad A., Motamed F., Moraveji A., Hooshmand M., Ashtiani MTH., Rezaei N.**  
Genotype-phenotype relationship in Iranian patients with cystic fibrosis  
*Turkish Journal of Gastroenterology* 2015; 26: 241 - 243

**Ploszaj T., Jerszynska B., Jedrychowska-Danska K., Lewandowska M., Kubiak D., Grzywnowicz K., Maslowska A., Witas HW.**  
Mitochondrial DNA genetic diversity and LCT-13910 and deltaF508 CFTR alleles typing in the medieval sample from Poland  
*HOMO-journal of Comparative Human Biology* 2015; 66: 229 - 250

**Terlizzi V., Camovale V., Castaldo G., Castellani C., Cirilli N., Colombo C., Corti F., Cresta F., D'Adda A., Lucarelli M., Lucidi V., Macchiaroli A., Madarena E., Padoan R., Quattrucci S., Salvatore D., Zarrilli F., Raia V.**  
Clinical expression of patients with the D1152H CFTR mutation  
*Journal of Cystic Fibrosis* 2015; 14: 447 - 452

**Tomati V., Sondo E., Armirotti A., Caci E., Pesce E., Marini M., Gianotti A., Jeon YJ., Cilli M., Pistorio A., Mastracci L., Ravazzolo R., Scholte B., Ronai Z., Galietta LJV., Pedemonte N.**  
Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation  
*Scientific Reports* 2015; 5: ArNo: 12138

## Growth & Development

**Erickson ML., Seigler N., McKie KT., McCully KK., Harris RA.**  
Skeletal muscle oxidative capacity in patients with cystic fibrosis  
*Experimental Physiology* 2015; 100: 545 - 552

**Putman MS., Baker JF., Uluer A., Herlyn K., Lapey A., Sicilian L., Tillotson AP., Gordon CM., Merkel PA., Finkelstein JS.**  
Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period  
*Journal of Cystic Fibrosis* 2015; 14: 526 – 532

## Immunology & Inflammation

**Bannon A., Zhang SD., Schock BC., Ennis M.**  
Cystic Fibrosis from Laboratory to Bedside: The Role of A20 in NF-kappa B-Mediated Inflammation  
*Medical Principles and Practice* 2015; 24: 301 - 310

**Cantin AM., Hartl D., Konstan MW., Chmiel JF.**  
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy  
*Journal of Cystic Fibrosis* 2015; 14: 419 - 430

**Carevic M., Singh A., Rieber N., Eickmeier O., Griese M., Hector A., Hartl D.**  
CXCR4(+) granulocytes reflect fungal cystic fibrosis lung disease  
*European Respiratory Journal* 2015; 46: 395 - 404

**Esther CR., Coakley RD., Henderson AG., Zhou YH., Wright FA., Boucher RC.**  
Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis  
*Chest* 2015; 148: 507 - 515

**Hardy CL., King SJ., Mifsud NA., Hedger MP., Phillips DJ., Mackay F., de Kretser DM., Wilson JW., Rolland JM., O'Hehir RE.**  
The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology  
*Immunology and Cell Biology* 2015; 93: 567 - 574

**Hussain S., Varelogianni G., Sarndahl E., Roomans GM.**  
N-acetylcysteine and azithromycin affect the innate immune response in cystic fibrosis bronchial epithelial cells in vitro  
*Experimental Lung Research* 2015; 41: 251 - 260

**Ingersoll SA., Laval J., Forrest OA., Preininger M., Brown MR., Arafat D., Gibson G., Tangpricha V., Tirouvanziam R.**  
Mature Cystic Fibrosis Airway Neutrophils Suppress T Cell Function: Evidence for a Role of Arginase 1 but Not Programmed Death-Ligand 1  
*Journal of Immunology* 2015; 194: 5520 - 5528

**Jovic S., Shikhagaie M., Morgelin M., Erjefalt JS., Kjellstrom S., Egesten A.**  
Osteopontin is increased in cystic fibrosis and can skew the functional balance between ELR-positive and ELR-negative CXC-chemokines  
*Journal of Cystic Fibrosis* 2015; 14: 453 - 463

**Lindberg U., Carlsson M., Hellmark T., Segelmark M.**  
BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients  
*Journal of Immunology Research* 2015; : ArNo: 947934

**Mormile R., Vittori G.**  
Cystic fibrosis lung disease and concomitant endometriosis: The final blow of interferon-gamma?  
*Immunology Letters* 2015; 166: 143 - 144

**Ogese MO., Saide K., Faulkner L., Whitaker P., Peckham D., Alfirevic A., Baker DM., Sette A., Pirmohamed M., Park BK., Naisbitt DJ.**  
HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis  
*Clinical And Experimental Allergy* 2015; 45: 1305 - 1316

**Rahman S., Gadjeva M.**  
Does NETosis contribute to the bacterial pathoadaptation in cystic fibrosis?  
*Frontiers In Immunology* 2014; 5: ArNo: 378

**Thomsen K., Christophersen L., Bjarnsholt T., Jensen PO., Moser C., Hoiby N.**  
Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils  
*Infection and Immunity* 2015; 83: 2686 - 2693

**Turowski JB., Pietrofesa RA., Lawson JA., Christofidou-Solomidou M., Hadjiliadis D.**

Flaxseed modulates inflammatory and oxidative stress biomarkers in cystic fibrosis: a pilot study  
*BMC Complementary And Alternative Medicine* 2015; 15: ArNo: 148

**Twigg MS., Brockbank S., Lowry P., FitzGerald SP., Taggart C., Weldon S.**

The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung  
*Mediators of Inflammation* 2015; : ArNo: 293053

## Liver Disease

**Bodewes FAJA., van der Doef HPJ., Houwen RHJ., Verkade HJ.**

Increase of Serum gamma-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease  
*Journal of Pediatric Gastroenterology and Nutrition* 2015; 61: 113 - 118

**Buxbaum J., Nguyen N., Kulkarni S., Palmer S., Rao A., Selby R.**

Multidisciplinary Treatment of Cystic Fibrosis-Related Recurrent Pyogenic Cholangitis (CF-RPC)  
*Digestive Diseases and Sciences* 2015; 60: 1801 - 1804

**Ciuca IM., Pop L., Ranetti AE., Popescu IM., Almajan-Guta B., Malita IM., Anghel I.**

Ursodeoxycholic Acid Effects on Cystic Fibrosis Liver Disease  
*Farmacia* 2015; 63: 543 - 547

**Sadler MD., Crotty P., Fatovich L., Wilson S., Rabin HR., Myers RP.**

Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis  
*Canadian Journal of Gastroenterology and Hepatology* 2015; 29: 139 - 144

## Microbiology

**Ahlgren HG., Benedetti A., Landry JS., Bernier J., Matouk E., Radzioch D., Lands LC., Rousseau S., Nguyen D.**

Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients  
*BMC Pulmonary Medicine* 2015; 15: ArNo: 67

**Ahmed GF., Elkhatib WF., Noreddin AM.**

Inhibition of Pseudomonas aeruginosa PAO1 adhesion to and invasion of A549 lung epithelial cells by natural extracts  
*Journal of Infection and Public Health* 2014; 7: 436 - 444

**Almblad H., Harrison JJ., Rybtke M., Groizeleau J., Givskov M., Parsek MR., Tolker-Nielsen T.**

The Cyclic AMP-Vfr Signaling Pathway in Pseudomonas aeruginosa Is Inhibited by Cyclic Di-GMP  
*Journal of Bacteriology* 2015; 197: 2190 - 2200

**Auerbach A., Kerem E., Assous MV., Picard E., Bar-Meir M.**

Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  
*Journal of Cystic Fibrosis* 2015; 14: 347 - 352

**Bandara HMHN., Nguyen D., Mugarala S., Osinski M., Smyth HDC.**

Magnetic fields suppress Pseudomonas aeruginosa biofilms and enhance ciprofloxacin activity  
*Biofouling* 2015; 31: 443 - 457

**Beaume M., Kohler T., Fontana T., Tognon M., Renzoni A., van Delden C.**

Metabolic pathways of Pseudomonas aeruginosa involved in competition with respiratory bacterial pathogens  
*Frontiers In Microbiology* 2015; 6: ArNo: 371

**Bouffartigues E., Moscoso JA., Duchesne R., Rosay T., Fito-Boncompte L., Gicquel G., Maillot O., Benard M., Bazire A., Brenner-Weiss G., Lesouhaitier O., Lerouge P., Dufour A., Orange N., Feuilloley MGJ., Overhage J., Filloux A., Che**

The absence of the Pseudomonas aeruginosa OprF protein leads to increased biofilm formation through variation in c-di-GMP level  
*Frontiers In Microbiology* 2015; 6: ArNo: 630

**Caldas RR., Le Gall F., Revert K., Rault G., Virmaux M., Gouriou S., Hery-Arnaud G., Barbier G., Boisrame S.**

Pseudomonas aeruginosa and Periodontal Pathogens in the Oral Cavity and Lungs of Cystic Fibrosis Patients: a Case-Control Study  
*Journal Of Clinical Microbiology* 2015; 53: 1898 - 1907

**Chabi ML., Goracci A., Roche N., Paugam A., Lupo A., Revel MP.**

Pulmonary aspergillosis  
*Diagnostic and Interventional Imaging* 2015; 96: 435 - 442

**Chin M., De Zoysa M., Slinger R., Gaudet E., Vandemheen KL., Chan F., Hyde L., Mah TF., Ferris W., Mallick R., Aaron SD.**

Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations  
*Journal of Cystic Fibrosis* 2015; 14: 482 - 489

**Chua SL., Hultqvist LD., Yuan MJ., Rybtke M., Nielsen TE., Givskov M., Tolker-Nielsen T., Yang L.**

In vitro and in vivo generation and characterization of Pseudomonas aeruginosa biofilm-dispersed cells via c-di-GMP manipulation  
*Nature Protocols* 2015; 10: 1165 - 1180

**Clark ST., Caballero JD., Cheang M., Coburn B., Wang PW., Donaldson SL., Zhang Y., Liu MY., Keshavjee S., Yau YCW., Waters VJ., Tullis DE., Guttman DS., Hwang DM.**

Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis  
*Scientific Reports* 2015; 5: ArNo: 10932

**Coburn B., Wang PW., Caballero JD., Clark ST., Brahma V., Donaldson S., Zhang Y., Surendra A., Gong YC., Tullis DE., Yau YCW., Waters VJ., Hwang DM., Guttman DS.**

Lung microbiota across age and disease stage in cystic fibrosis  
*Scientific Reports* 2015; 5: ArNo: 10241

**Cuthbertson L., Rogers GB., Walker AW., Oliver A., Hoffman LR., Carroll MP., Parkhill J., Bruce KD., van der Gast CJ.**

Implications of multiple freeze-thawing on respiratory samples for culture-independent analyses  
*Journal of Cystic Fibrosis* 2015; 14: 464 - 467

**Dagan A., Keller N., Vilozni D., Ramon-Saraf R., Bar BE., Sarouk I., Ashkenazi M., Lavie M., Efrati O.**

Nocardia Colonization: A Risk Factor for Lung Deterioration in Cystic Fibrosis Patients?  
*Medical Science Monitor* 2015; 21: 1889 - 1894

**Dolfi S., Sveronis A., Silipo A., Rizzo R., Cescutti P.**

A novel rhamno-mannan exopolysaccharide isolated from biofilms of Burkholderia multivorans C1576  
*Carbohydrate Research* 2015; 411: 42 - 48

**Dupont C., Michon AL., Jumas-Bilak E., Norskov-Lauritsen N., Chiron R., Marchandin H.**

Inpatient diversity of Achromobacter spp. involved in chronic colonization of Cystic Fibrosis airways  
*Infection Genetics and Evolution* 2015; 32: 214 - 223

**Elbom JS., Geller DE., Conrad D., Aaron SD., Smyth AR., Fischer R., Kerem E., Bell SC., Loutit JS., Dudley MN., Morgan EE., VanDevanter DR., Flume PA.**

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients  
*Journal of Cystic Fibrosis* 2015; 14: 507 - 514

- Emond MJ., Louie T., Emerson J., Chong JX., Mathias RA., Knowles MR., Rieder MJ., Tabor HK., Nickerson DA., Barnes KC., Go L., Gibson RL., Bamshad MJ.**  
Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic *Pseudomonas aeruginosa* Infection in Cystic Fibrosis  
*PLoS Genetics* 2015; 11: 6:1005273
- Ferreira JAG., Penner JC., Moss RB., Haagensen JAJ., Clemons KV., Spormann AM., Nazik H., Cohen K., Banaei N., Carolino E., Stevens DA.**  
Inhibition of *Aspergillus fumigatus* and Its Biofilm by *Pseudomonas aeruginosa* Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium  
*PLoS One* 2015; 10: 8:e0134692
- Filkins LM., Graber JA., Olson DG., Dolben EL., Lynd LR., Bhujju S., O'Toole GA.**  
Coculture of *Staphylococcus aureus* with *Pseudomonas aeruginosa* Drives S-aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model  
*Journal of Bacteriology* 2015; 197: 2252 - 2264
- Flight WG., Smith A., Paisey C., Marchesi JR., Bull MJ., Norville PJ., Mutton KJ., Webb AK., Bright-Thomas RJ., Jones AM., Mahenthiralingam E.**  
Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis  
*Journal of Clinical Microbiology* 2015; 53: 2022 - 2029
- Greenberger PA., Bush RK., Demain JG., Luong A., Slavin RG., Knutsen AP.**  
Allergic Bronchopulmonary Aspergillosis  
*Journal of Allergy and Clinical Immunology-in Practice* 2014; 2: 703 - 708
- Hammond JH., Dolben EF., Smith TJ., Bhujju S., Hogan DA.**  
Links between Anr and Quorum Sensing in *Pseudomonas aeruginosa* Biofilms  
*Journal of Bacteriology* 2015; 197: 2810 - 2820
- Hao YA., Murphy K., Lo RY., Khursigara CM., Lam JS.**  
Single-Nucleotide Polymorphisms Found in the migA and wbpX Glycosyltransferase Genes Account for the Intrinsic Lipopolysaccharide Defects Exhibited by *Pseudomonas aeruginosa* PA14  
*Journal of Bacteriology* 2015; 197: 2780 - 2791
- Harmer CJ., Wynn M., Pinto R., Cordwell S., Rose BR., Harbour C., Triccas JA., Manos J.**  
Homogentisate 1-2-Dioxygenase Downregulation in the Chronic Persistence of *Pseudomonas aeruginosa* Australian Epidemic Strain-1 in the CF Lung  
*PLoS One* 2015; 10: 8:e0134229
- Hoppe JE., Towler EE., Wagner BD., Accurso FJ., Sagel SD., Zemanick ET.**  
Sputum Induction Improves Detection of Pathogens in Children With Cystic Fibrosis  
*Pediatric Pulmonology* 2015; 50: 638 - 646
- Hraiech S., Bregeon F., Rolain JM.**  
Bacteriophage-based therapy in cystic fibrosis-associated *Pseudomonas aeruginosa* infections: rationale and current status  
*Drug Design Development and Therapy* 2015; 9: 3653 - 3663
- James CE., Davies EV., Fothergill JL., Walshaw MJ., Beale CM., Brockhurst MA., Winstanley C.**  
Lytic activity by temperate phages of *Pseudomonas aeruginosa* in long-term cystic fibrosis chronic lung infections  
*ISME Journal* 2015; 9: 1391 - 1398
- Johansson E., Welinder-Olsson C., Gilljam M., Pourcel C., Lindblad A.**  
Genotyping of *Pseudomonas aeruginosa* reveals high diversity, stability over time and good outcome of eradication  
*Journal of Cystic Fibrosis* 2015; 14: 353 - 360
- Jolly AL., Takawira D., Oke OO., Whiteside SA., Chang SW., Wen ER., Quach K., Evans DJ., Fleiszig SMJ.**  
*Pseudomonas aeruginosa*-Induced Bleb-Niche Formation in Epithelial Cells Is Independent of Actinomyosin Contraction and Enhanced by Loss of Cystic Fibrosis Transmembrane-Conductance Regulator Osmoregulatory Function  
*MBio* 2015; 6: 2:e02533
- Keravec M., Mounier J., Prestat E., Vallet S., Jansson JK., Burgaud G., Rosec S., Gouriou S., Rault G., Coton E., Barbier G., Hery-Arnaud G.**  
Insights into the respiratory tract microbiota of patients with cystic fibrosis during early *Pseudomonas aeruginosa* colonization  
*Springerplus* 2015; 4: ArNo: 405
- Kidd TJ., Magalhaes RJS., Paynter S., Bell SC.**  
The social network of cystic fibrosis centre care and shared *Pseudomonas aeruginosa* strain infection: a cross-sectional analysis  
*Lancet Respiratory Medicine* 2015; 3: 640 - 650
- Kidd TJ., Ramsay KA., Vidmar S., Carlin JB., Bell SC., Wainwright CE., Grimwood K., Wainwright CE., Grimwood K., Francis PW., Dakin C., Cheney J., George N., Carlin JB., Robertson CF., Vidmar S., Moodie M., Carzino R., Carter R., A**  
*Pseudomonas aeruginosa* genotypes acquired by children with cystic fibrosis by age 5-years  
*Journal of Cystic Fibrosis* 2015; 14: 361 - 369
- Klinger-Strobel M., Lautenschlager C., Fischer D., Mainz JG., Bruns T., Tuchscher L., Pletz MW., Makarewicz O.**  
Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis - where do we stand?  
*Expert Opinion on Drug Delivery* 2015; 12: 1351 - 1374
- Kriegeskorte A., Block D., Kahl BC.**  
Response to "In vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response"  
*Mucosal Immunology* 2015; 8: 696
- Lagares A., Agaras B., Bettiol MP., Gatti BM., Valverde C.**  
A cultivation-independent PCR-RFLP assay targeting oprF gene for detection and identification of *Pseudomonas* spp. in samples from fibrocystic pediatric patients  
*Journal of Microbiological Methods* 2015; 114: 66 - 74
- Lopes SP., Azevedo NF., Pereira MO.**  
Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy  
*Critical Reviews in Microbiology* 2015; 41: 353 - 365
- Lopez-Collazo E., Jurado T., Caballero JD., Perez-Vazquez M., Vindel A., Hernandez-Jimenez E., Tamames J., Cubillos-Zapata C., Manrique M., Tobes R., Maiz L., Canton R., Baquero F., del Campo R.**  
Response to "In vivo attenuation and genetic evolution of a ST247-SCCmecI MRSA clone after 13 years of pathogenic bronchopulmonary colonization in a patient with cystic fibrosis: implications of the innate immune response"  
*Mucosal Immunology* 2015; 8: 697 - 698
- Lupo A., Isis E., Tinguely R., Endimiani A.**  
Clonality and antimicrobial susceptibility of *Burkholderia cepacia* complex isolates collected from cystic fibrosis patients during 1998-2013 in Bern, Switzerland  
*New Microbiologica* 2015; 38: 281 - 288
- Masoud-Landgraf L., Jöhler S., Badura A., Feierl G., Luxner J., Wagner-Eibel U., Eber E., Zarfel G., Grisold AJ.**  
Genetic and Phenotypic Characteristics of *Staphylococcus aureus* Isolates from Cystic Fibrosis Patients in Austria  
*Respiration* 2015; 89: 390 - 395

**Matos T., Cerar T., Praprotnik M., Krivec U., Pirs M.**

First recovery of *Rasamsonia argillacea* species complex isolated in adolescent patient with cystic fibrosis in Slovenia - case report and review of literature

*Mycoses* 2015; 58: 506 - 510

**Mei-Zahav M., Livnat G., Bentur L., Mussaffi H., Prais D., Stafler P., Bar-On O., Steuer G., Blau H.**

The spectrum of nocardia lung disease in cystic fibrosis

*Pediatric Infectious Disease Journal* 2015; 34: 909 - 911

**Mihai MM., Holban AM., Giurcaneanu C., Popa LG., Oanea RM., Lazar V., Chifiriuc MC., Popa M., Popa MI.**

Microbial Biofilms: Impact on the Pathogenesis of Periodontitis, Cystic Fibrosis, Chronic Wounds and Medical Device-Related Infections

*Current Topics In Medicinal Chemistry* 2015; 15: 1552 - 1576

**Moradali MF., Donati I., Sims IM., Ghods S., Rehm BHA.**

Alginate Polymerization and Modification Are Linked in *Pseudomonas aeruginosa*

*MBio* 2015; 6: 3:e00453-15

**Morelli P., De Alessandri A., Manno G., Marchese A., Bandettini R., Bassi M., Lobello R., Minicucci L.**

Characterization of *Staphylococcus aureus* small colony variant strains isolated from Italian patients attending a regional cystic fibrosis care centre

*New Microbiologica* 2015; 38: 235 - 243

**Muller FM., Bend J., Huttegger I., Moller A., Schwarz C., Abele-Horn M., Ballmann M., Bargon J., Baumann I., Bremer W., Bruns R., Brunsmann F., Fischer R., Geidel C., Hebestreit H., Hirche TO., Hogardt M., Illing S., et al**

S3 guidelines on pulmonary disease in cystic fibrosis. Module 1: diagnostics and therapy after initial detection of *Pseudomonas aeruginosa*

*Monatsschrift Kinderheilkunde* 2015; 163: 590 - 599

**Noni M., Katelari A., Kaditis A., Theochari I., Lympari I., Alexandrou-Athanassoulis H., Doudounakis SE., Dimopoulos G.**

*Candida albicans* chronic colonisation in cystic fibrosis may be associated with inhaled antibiotics

*Mycoses* 2015; 58: 416 - 421

**Olszak T., Zarnowiec P., Kaca W., Danis-Wlodarczyk K., Augustyniak D., Drevinek P., de Soya A., McClean S., Drulis-Kawa Z.**

In vitro and in vivo antibacterial activity of environmental bacteriophages against *Pseudomonas aeruginosa* strains from cystic fibrosis patients

*Applied Microbiology and Biotechnology* 2015; 99: 6021 - 6033

**Parkins MD., Floto RA.**

Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis

*Journal of Cystic Fibrosis* 2015; 14: 293 - 304

**Pricope D., Deneuve E., Frain S., Chevrier S., Belaz S., Roussey M., Gangneux JP.**

Indoor fungal exposure: What impact on clinical and biological status regarding *Aspergillus* during cystic fibrosis

*Journal de Mycologie Medicale* 2015; 25: 136 - 142

**Purdy-Gibson ME., France M., Hundley TC., Eid N., Remold SK.**

*Pseudomonas aeruginosa* in CF and non-CF homes is found predominantly in drains

*Journal of Cystic Fibrosis* 2015; 14: 341 - 346

**Rahmani-Badi A., Sepehr S., Fallahi H., Heidari-Keshner S.**

Dissection of the cis-2-decenoic acid signaling network in *Pseudomonas aeruginosa* using microarray technique

*Frontiers In Microbiology* 2015; 6: ArNo: 383

**Rodriguez-Nava V., Durupt S., Chyderiotis S., Freydiere AM., Karsenty J., de Montclos M., Reix P., Durieu I., Nove-Josserand R., Chiron R., Bremont F., Tetu L., Murriss M., Terru D., Godreuil S., Bergeron E., Freney J., Boiron P., Va**

A French multicentric study and review of pulmonary *Nocardia* spp. in cystic fibrosis patients

*Medical Microbiology and Immunology* 2015; 204: 493 - 504

**Sabino R., Ferreira JAG., Moss RB., Valente J., Verissimo C., Carolino E., Clemons KV., Everson C., Banaei N., Penner J., Stevens DA.**

Molecular epidemiology of *Aspergillus* collected from cystic fibrosis patients

*Journal of Cystic Fibrosis* 2015; 14: 474 - 481

**Selin C., Stietz MS., Blanchard JE., Gehrke SS., Bernard S., Hall DG., Brown ED., Cardona ST.**

A Pipeline for Screening Small Molecules with Growth Inhibitory Activity against *Burkholderia cenocepacia*

*PLoS One* 2015; 10: 6:e0128587

**Shestivska V., Dryahina K., Nunvar J., Sovova K., Elhottova D., Nemecek A., Smith D., Spanel P.**

Quantitative analysis of volatile metabolites released in vitro by bacteria of the genus *Stenotrophomonas* for identification of breath biomarkers of respiratory infection in cystic fibrosis

*Journal of Breath Research* 2015; 9: 2:027104

**Shommu NS., Vogel HJ., Storey DG.**

Potential of metabolomics to reveal *Burkholderia cepacia* complex pathogenesis and antibiotic resistance

*Frontiers In Microbiology* 2015; 6: ArNo: 668

**Stanton BA., Coutermarsh B., Barnaby R., Hogan D.**

*Pseudomonas aeruginosa* Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells

*PLoS One* 2015; 10: 5:e0127742

**Thornton CS., Brown EL., Alcantara J., Rabin HR., Parkins MD.**

Prevalence and impact of *Streptococcus pneumoniae* in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study

*BMC Pulmonary Medicine* 2015; 15: ArNo: 49

**Trinh NTN., Bilodeau C., Maille E., Ruffin M., Quintal MC., Desrosiers MY., Rousseau S., Brochiero E.**

Deleterious impact of *Pseudomonas aeruginosa* on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells

*European Respiratory Journal* 2015; 45: 1590 - 1602

**Voronina OL., Kunda MS., Ryzhova NN., Aksenova EI., Semenov AN., Lasareva AV., Amelina EL., Chuchalin AG., Lunin VG., Gintsburg AL.**

The Variability of the Order *Burkholderiales* Representatives in the Healthcare Units

*Biomed Research International* 2015; : ArNo: 680210

**Yonker LM., Cigana C., Hurley BP., Bragonzi A.**

Host-pathogen interplay in the respiratory environment of cystic fibrosis

*Journal of Cystic Fibrosis* 2015; 14: 431 - 439

## Nutrition

**Del Ciampo IRL., Del Ciampo LA., Sawamura R., de Oliveira LR., Fernandes MIM.**

Nutritional status of adolescents with cystic fibrosis treated at a reference center in the southeast region of Brazil

*Italian Journal of Pediatrics* 2015; 41: ArNo: 51

**Krzyzanowska P., Pogorzelski A., Skorupa W., Moczko J., Grebowiec P., Walkowiak J.**

Exogenous and endogenous determinants of vitamin K status in cystic fibrosis

*Scientific Reports* 2015; 5: ArNo: 12000

**Loukou I., Boutopoulou B., Fouzas S., Douros K.**

Vitamin D and Cystic Fibrosis Lung Disease  
*Mini-reviews in Medicinal Chemistry* 2015; 15: 974 - 983

**Powers SW., Stark LJ., Chamberlin LA., Filigno SS., Sullivan SM., Lemanek KL., Butcher JL., Driscoll KA., Daines CL., Brody AS., Schindler T., Konstan MW., McCoy KS., Nasr SZ., Castile RG., Acton JD., Wooldridge JL., Ksenich RA., Sz**

Behavioral and Nutritional Treatment for Preschool-Aged Children With Cystic Fibrosis A Randomized Clinical Trial  
*JAMA Pediatrics* 2015; 169: 5:e150636

**Ramirez I., Filbrun A., Hasan A., Kidwell KM., Nasr SZ.**

Improving nutritional status in a pediatric cystic fibrosis center  
*Pediatric Pulmonology* 2015; 50: 544 - 551

**Schindler T., Michel S., Wilson AWM.**

Nutrition Management of Cystic Fibrosis in the 21st Century  
*Nutrition In Clinical Practice* 2015; 30: 488 - 500

**Sexauer WP., Hadeh A., Ohman-Strickland PA., Zanni RL., Varlotta L., Holsclaw D., Fiel S., Graff GR., Atlas A., Bisberg D., Hadjiliadis D., Michel SH., Mintz D., Chakraborty R., Marra B., Lomas P., Ward T., Sassman M., Imbesi GC.,**

Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis  
*Journal of Cystic Fibrosis* 2015; 14: 497 - 506

**Sockrider MM.**

Optimizing Nutritional Health Through Behavioral Intervention in Young Children With Cystic Fibrosis  
*JAMA Pediatrics* 2015; 169: 5:e150644

**Visca A., Bishop CT., Hilton S., Hudson VM.**

Oral Reduced L-Glutathione Improves Growth in Pediatric Cystic Fibrosis Patients  
*Journal of Pediatric Gastroenterology and Nutrition* 2015; 60: 802 - 810

## Physiotherapy

**Dwyer TJ., Robbins L., Kelly P., Piper AJ., Bell SC., Bye PTP.**

Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial  
*Journal of Physiotherapy* 2015; 61: 142 - 147

**Stanford G., Parrott H., Bilton D., Agent P.**

Positive pressure - analysing the effect of the addition of non-invasive ventilation (NIV) to home airway clearance techniques (ACT) in adult cystic fibrosis (CF) patients  
*Physiotherapy Theory and Practice* 2015; 31: 270 - 274

**Stanojevic S., Jensen R., Sundaralingam D., Salazar JG., Yammine S., Singer F., Latzin P., Amin R., Subbarao P., Gustafsson P., Ratjen F.**

Alternative outcomes for the multiple breath washout in children with CF  
*Journal of Cystic Fibrosis* 2015; 14: 490 - 496

## Psychosocial

**Abbott J., Elborn JS., Georgiopoulos AM., Goldbeck L., Marshall BC., Sadoska KA., Smith BA., Quittner AL.**

Cystic Fibrosis Foundation and European Cystic Fibrosis Society, Survey of cystic fibrosis mental health care delivery  
*Journal of Cystic Fibrosis* 2015; 14: 533 - 539

**Alpem AN., Brumback LC., Ratjen F., Rosenfeld M., Davis SD., Quittner AL.**

Initial evaluation of the Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) in infants and young children  
*Journal of Cystic Fibrosis* 2015; 14: 403 - 411

**Braido F., Baiardini I., Sumberesi M., Canonica GW., Blasi F., Castellani C.**

Public awareness on cystic fibrosis: results from a national pragmatic survey  
*European Respiratory Journal* 2015; 46: 264 - 267

**Chevreul K., Brigham KB., Michel M., Rault G.**

Costs and health-related quality of life of patients with cystic fibrosis and their carers in France  
*Journal of Cystic Fibrosis* 2015; 14: 384 - 391

**Douglas T., Jordan B., Priddis L., Anderson V., Sheehan J., Kane RT., Massie J., Branch-Smith C., Shields L.**

Protocol for a study of the psychosocial determinants of health in early childhood among children with cystic fibrosis  
*Journal Of Advanced Nursing* 2015; 71: 1704 - 1716

**Driscoll KA., Modi AC., Filigno SS., Brannon EE., Chamberlin LA., Stark LJ., Powers SW.**

Quality of life in children with CF: Psychometrics and relations with stress and mealtime behaviors  
*Pediatric Pulmonology* 2015; 50: 560 - 567

**Fidika A., Herle M., Herschbach P., Goldbeck L.**

Fear of disease progression questionnaire for parents: Psychometric properties based on a sample of caregivers of children and adolescents with cystic fibrosis  
*Journal of Psychosomatic Research* 2015; 79: 49 - 54

**Garcia G., Oliva M., Smith BA.**

Survey of collaborative mental health providers in cystic fibrosis centers in the United States  
*General Hospital Psychiatry* 2015; 37: 240 - 244

**Havermans T., De Croock I., Vercruyse T., Goethals E., Van Diest I.**

Belgian siblings of children with a chronic illness: Is their quality of life different from their peers?  
*Journal of Child Health Care* 2015; 19: 154 - 166

**Havermans T., Tack J., Vertommen A., Proesmans M., de Boeck K.**

Breaking bad news, the diagnosis of cystic fibrosis in childhood  
*Journal of Cystic Fibrosis* 2015; 14: 540 - 546

**Homa K., Sadoska KA., Marrow LC., Marshall BC.**

Experience of care from the perspective of individuals with cystic fibrosis and families: Results from 70 CF Foundation accredited programs in the USA  
*Journal of Cystic Fibrosis* 2015; 14: 515 - 522

**Jones ST., Babiker NA., Gardner EM., Royle J., Curley RA., Hoo ZH., Wildman MJ.**

Promoting adherence to nebulized therapy in cystic fibrosis: poster development and a qualitative exploration of adherence  
*Patient Preference and Adherence* 2015; 9: 1109 - 1120

**Kir D., Gupta S., Jolly G., Kalaivani M., Lodha R., Kabra SK.**

Health related quality of life in Indian children with cystic fibrosis  
*Indian Pediatrics* 2015; 52: 403 - 408

**Moco VJR., Lopes AJ., Vigario PD., de Almeida VP., de Menezes SLS., Guimaraes FS.**

Pulmonary function, functional capacity and quality of life in adults with cystic fibrosis  
*Revista Portuguesa de Pneumologia* 2015; 21: 198 - 202

**Pakhale S., Baron J., Armstrong M., Tasca G., Gaudet E., Aaron S., Cameron W., Balfour L.**

A Cross-Sectional Study of the Psychological Needs of Adults Living with Cystic Fibrosis  
*PLoS One* 2015; 10: 6:e0127944

**Quon BS., Bentham WD., Unutzer J., Chan YF., Goss CH., Aitken ML.**

Prevalence of Symptoms of Depression and Anxiety in Adults With Cystic Fibrosis Based on the PHQ-9 and GAD-7 Screening Questionnaires  
*Psychosomatics* 2015; 56: 345 - 353

**Temme R., Gruber A., Johnson M., Read L., Lu Y., McNamara J.**  
Assessment of Parental Understanding of Positive Newborn Screening Results and Carrier Status for Cystic Fibrosis with the use of a Short Educational Video  
*Journal of Genetic Counseling* 2015; 24: 473 – 481

## Pulmonology

**Aanaes K., Eickhardt S., Johansen HK., von Buchwald C., Skov M., Hoiby N., Bjarnsholt T.**  
Sinus biofilms in patients with cystic fibrosis: is adjusted eradication therapy needed?  
*European Archives of Oto-Rhino-Laryngology* 2015; 272: 2291 - 2297

**Beer H., Southern KW., Swift AC.**  
Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2015; : 6:CD008253

**Chauvet S., Traboulsi W., Thevenon L., Kouadri A., Feige JJ., Camara B., Alfaidy N., Benharouga M.**  
EG-VEGF, BV8, and their receptor expression in human bronchi and their modification in cystic fibrosis: Impact of CFTR mutation (delF508)  
*American Journal of Physiology-Lung Cellular and Molecular Physiology* 2015; 309: L314 - L322

**Cogen J., Emerson J., Sanders DB., Ren C., Schechter MS., Gibson RL., Morgan W., Rosenfeld M.**  
Risk factors for lung function decline in a large cohort of young cystic fibrosis patients  
*Pediatric Pulmonology* 2015; 50: 763 - 770

**Do BA., Lands LC., Mascarella MA., Fanous A., Saint-Martin C., Manoukian JJ., Nguyen LHP.**  
Lund-Mackay and modified Lund-Mackay score for sinus surgery in children with cystic fibrosis  
*International Journal of Pediatric Otorhinolaryngology* 2015; 79: 1341 - 1345

**Garratt LW., Sutanto EN., Ling KM., Looi K., Iosifidis T., Martinovich KM., Shaw NC., Kicic-Starcevic E., Knight DA., Ranganathan S., Stick SM., Kicic A.**  
Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis  
*European Respiratory Journal* 2015; 46: 384 - 394

**Hatziagorou E., Avramidou V., Kirvassilis F., Tsanakas J.**  
Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis  
*Hippokratia* 2015; 19: 47 - 52

**Hentschel J., Fischer N., Janhsen WK., Markert UR., Lehmann T., Sonnemann J., Boer K., Pfister W., Hipler UC., Mainz JG.**  
Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions  
*Journal of Cystic Fibrosis* 2015; 14: 324 - 333

**Justicia JL., Sole A., Quintana-Gallego E., Gartner S., de Gracia J., Prados C., Maiz L.**  
Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice  
*Expert Review of Respiratory Medicine* 2015; 9: 183 - 194

**Kim RJT., Park L., Wood AJ., Yin T., Jain R., Douglas RG.**  
Chronic rhinosinusitis and cystic fibrosis: the interaction between sinus bacteria and mucosal immunity  
*International Forum of Allergy & Rhinology* 2015; 5: 380 - 385

**Ma DC., Yoon AJ., Faull KF., Desharnais R., Zemanick ET., Porter E.**  
Cholesteryl Esters Are Elevated in the Lipid Fraction of Bronchoalveolar Lavage Fluid Collected from Pediatric Cystic Fibrosis Patients  
*PLoS One* 2015; 10: 4:e0125326

**Mulcahy EM., Hudson JB., Beggs SA., Reid DW., Roddam LF., Cooley MA.**  
High Peripheral Blood Th17 Percent Associated with Poor Lung Function in Cystic Fibrosis  
*PLoS One* 2015; 10: 3:e0120912

**O'Neill K., Bradley JM., Johnston E., McGrath S., McIlreavey L., Rowan S., Reid A., Bradbury I., Einarsson G., Elborn JS., Tunney MM.**  
Reduced Bacterial Colony Count of Anaerobic Bacteria Is Associated with a Worsening in Lung Clearance Index and Inflammation in Cystic Fibrosis  
*PLoS One* 2015; 10: 5:e0126980

**Stanojevic S., Bilton D., McDonald A., Stocks J., Aurora P., Prasad A., Cole TJ., Davies G.**  
Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis  
*European Respiratory Journal* 2015; 46: 262 - 264

**Wagener JS., Elkin EP., Pasta DJ., Schechter MS., Konstan MW., Morgan WJ.**  
Pulmonary function outcomes for assessing cystic fibrosis care  
*Journal of Cystic Fibrosis* 2015; 14: 376 - 383

**Woestenenk JW., Broos N., Stellato RK., Arets HGM., van der Ent CK., Houwen RHJ.**  
Serum retinol levels and pulmonary function in children and adolescents with cystic fibrosis  
*Journal of Cystic Fibrosis* 2015; 14: 392 - 397

**Zhao JC., Evans CR., Carmody LA., Lipuma JJ.**  
Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis  
*Journal of Cystic Fibrosis* 2015; 14: 468 - 473

## Radiology

**Engjom T., Erchinger F., Laerum BN., Tjora E., Gilja OH., Dimcevski G.**  
Ultrasound Echo-Intensity Predicts Severe Pancreatic Affection in Cystic Fibrosis Patients  
*Plos One* 2015; 10: 3:e0121121

**Loeve M., Rosenow T., Gorbunova V., Hop WCJ., Tiddens HAWM., de Bruijne M.**  
Reversibility of trapped air on chest computed tomography in cystic fibrosis patients  
*European Journal of Radiology* 2015; 84: 1184 - 1190

**Paulin GA., Svenningsen S., Jobse BN., Mohan S., Kirby M., Lewis JF., Parraga G.**  
Differences in hyperpolarized He-3 ventilation imaging after 4 years in adults with cystic fibrosis  
*Journal of Magnetic Resonance Imaging* 2015; 41: 1701 - 1707

**Rosenow T., Oudraad MCJ., Murray CP., Turkovic L., Kuo W., de Bruijne M., Ranganathan SC., Tiddens HAWM., Stick SM.**  
PRAGMA-CF A Quantitative Structural Lung Disease Computed Tomography Outcome in Young Children with Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine* 2015; 191: 1158 - 1165

**Sheikh SI., Long FR., Flucke R., Ryan-Wenger NA., Hayes D., McCoy KS.**  
Changes in Pulmonary Function and Controlled Ventilation-High Resolution CT of Chest After Antibiotic Therapy in Infants and Young Children with Cystic Fibrosis  
*Lung* 2015; 193: 421 - 428

## Screening

**Kay DM., Langfelder-Schwind E., DeCelle-Germana J., Sharp JK., Maloney B., Tavakoli NP., Saavedra-Matiz CA., Krein LM., Caggana M., Kier C.**

Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening  
*Pediatric Pulmonology* 2015; 50: 771 - 780

**Ooi CY., Castellani C., Keenan K., Avolio J., Volpi S., Boland M., Kovesi T., Bjornson C., Chilvers MA., Morgan L., van Wylick R., Kent S., Price A., Solomon M., Tam K., Taylor L., Malitt KA., Ratjen F., Durie PR., Gonska T.**

Inconclusive Diagnosis of Cystic Fibrosis After Newborn Screening  
*Pediatrics* 2015; 135: E1377 - E1385

**Ren CL., Fink AK., Petren K., Borowitz DS., McColley SA., Sanders DB., Rosenfeld M., Marshall BC.**

Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening  
*Pediatrics* 2015; 135: E1386 - E1392

**Sommerburg O., Hammermann J., Lindner M., Stahl M., Muckenthaler M., Kohlmüller D., Happich M., Kulozik AE., Stopsack M., Gahr M., Hoffmann GF., Mall MA.**

Five Years of Experience With Biochemical Cystic Fibrosis Newborn Screening Based on IRT/PAP in Germany  
*Pediatric Pulmonology* 2015; 50: 655 - 664

## Therapy

**Barry PJ., Jones AM.**

New and Emerging Treatments for Cystic Fibrosis  
*Drugs* 2015; 75: 1165 - 1175

**Bilton D.**

A new chapter in therapy for cystic fibrosis  
*Lancet Respiratory Medicine* 2015; 3: E20

**Corvol H., Taytard J., Tabary O., Le Rouzic P., Guillot L., Clement A.**

Challenges of personalized medicine for cystic fibrosis  
*Archives de Pédiatrie* 2015; 22: 778 - 786

**Moss RB., Flume PA., Elborn JS., Cooke J., Rowe SM., McColley SA., Rubenstein RC., Higgins M.**

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial  
*Lancet Respiratory Medicine* 2015; 3: 524 - 533

**Quittner A., Suthoff E., Rendas-Baum R., Bayliss MS., Sermet-Gaudelus I., Castiglione B., Vera-Llonch M.**

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial  
*Health and Quality of Life Outcomes* 2015; 13: ArNo: 93

**Thaker V., Haagenen AL., Carter B., Fedorowicz Z., Houston BW.**

Recombinant growth hormone therapy for cystic fibrosis in children and young adults  
*Cochrane Database of Systematic Reviews* 2015; : 5:CD008901

**Tildy BE., Rogers DF.**

Therapeutic Options for Hydrating Airway Mucus in Cystic Fibrosis  
*Pharmacology* 2015; 95: 117 - 132

**Vreede CL., Berkhout MC., Sprij AJ., Fokkens WJ., Heijerman HGM.**

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N  
*Journal of Cystic Fibrosis* 2015; 14: 412 - 413

**Wainwright CE., Elborn JS., Ramsey BW., Marigowda G., Huang X., Cipolli M., Colombo C., Davies JC., De Boeck K., Flume PA., Konstan MW., McColley SA., Mccoy K., McKone EF., Munck A., Ratjen F., Rowe SM., Waltz D., Boyle MP.**

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR  
*New England Journal Of Medicine* 2015; 373: 220 - 231

## Transplantation

**Eigner W., Mesteri I., Tribl B., Ba-Ssalamah A., Friedl J., Trauner M., Kazemi-Shirazi L.**

Intraductal papillary mucinous neoplasm of the pancreas in an adult patient with cystic fibrosis after double-lung transplantation  
*Journal of Cystic Fibrosis* 2015; 14: 523 - 525

**Hayes D., Kirkby S., Whitson BA., Black SM., Sheikh SI., Tobias JD., Mansour HM., Kopp BT.**

Mortality Risk and Pulmonary Function in Adults With Cystic Fibrosis at Time of Wait Listing for Lung Transplantation  
*Annals of Thoracic Surgery* 2015; 100: 474 - 479

**Merlo CA., Clark SC., Arnaoutakis GJ., Yonan N., Thomas D., Simon A., Thompson R., Thomas H., Orens J., Shah AS.**

National Healthcare Delivery Systems Influence Lung Transplant Outcomes for Cystic Fibrosis  
*American Journal of Transplantation* 2015; 15: 1948 - 1957

**Mets OM., Roothaan SM., Bronsveld I., Luijk B., van de Graaf EA., Vink A., de Jong PA.**

Emphysema Is Common in Lungs of Cystic Fibrosis Lung Transplantation Patients: A Histopathological and Computed Tomography Study  
*PLoS One* 2015; 10: e0128062

**Salizzoni S., Pilewski J., Toyoda Y.**

Lung Transplant for a Patient With Cystic Fibrosis and Active Burkholderia cenocepacia Pneumonia  
*Experimental and Clinical Transplantation* 2014; 12: 487 - 489

**Soto GAC., Ruiz-Antoran B., Laporta R., Sancho A., Lazaro MT., Herrera CP., Salcedo I., Cos MA., Torres F., Usetti P., Avendano-Sola C.**

Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice- to once-daily tacrolimus oral administration  
*European Journal of Clinical Pharmacology* 2015; 71: 715 - 722

**Wang XX., Feng MR., Nguyen H., Smith DE., Cibrik DM., Park JM.**

Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis  
*European Journal of Clinical Pharmacology* 2015; 71: 673 - 679

## Urology

**Burge AT., Holland AE., Sherburn M., Wilson J., Cox NS., Rasekaba TM., McAleer R., Morton JM., Button BM.**

Prevalence and impact of urinary incontinence in men with cystic fibrosis  
*Physiotherapy* 2015; 101: 166 - 170